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Gamma Interferon Induces Monocytoid
Differentiation in the HL-60 Cell Line
Edward D. Ball, Paul M. Guyre, Li Shen, John M. Glynn,
Charles R. Maliszewski, Paul E. Baker,
and Michael W. Fanger
Departments ofMicrobiology, Medicine, and Physiology,
Dartmouth Medical School, Hanover, New Hampshire 03756;
Department of Veterinary Research, Montana State University,
Bozeman, Montana 59715
Abstract. We investigated the ability ofpurified,
recombinant DNA-derived interferons (IFN) to induce
phenotypic changes in cells of the HL-60 promyelocytic
leukemia cell line. Changes in cell surface markers de-
tected by monoclonal antibodies as well as morphologic,
histochemical, and functional changes were monitored.
We found that gamma (y)IFN, but not alpha (a) or beta
(3)IFN, induced the expression of antigens characteristic
of monocytes and granulocytes (AML-2-23, 63D3, and
61 D3), as well as changes in morphology consistent with
monocytoid differentiation. These included induction of
a-naphthyl acetate esterase, increased cell size, and a de-
crease in azurophilic granules. The y-IFN dose depen-
dency and time course ofthe effect on antigen expression
suggest that de novo protein synthesis was induced by y-
IFN. The activity of -y-IFN and of mixed-lymphocyte
culture supernatant was blocked by a monoclonal anti-
body to y-IFN. Significant augmentation in the ability
ofthe HL-60 cells to mediate antibody-dependent cellular
cytotoxicity was induced by y-IFN. These findings suggest
that y-IFN plays a role in the regulation of hematopoiesis.
Introduction
A number of studies have documented the ability of the HL-
60 promyelocytic leukemia cell line to differentiate along either
a granulocytic or monocytic pathway, depending upon the in-
ducing agent used (1-4). Polar planar substances such as dimethyl
Receivedfor publication 22 September 1983 and in revisedform 8 De-
cember 1983.
sulfoxide (DMSO)' or dimethylformamide and retinoic acid
can induce striking granulocytic differentiation (1, 2), while
phorbol diesters and supernatants from stimulated lymphocytes
have been shown to cause these cells to undergo monocytoid
differentiation (3, 4). Changes concomitant with morphologic
differentiation also occur in the expression of cell surface an-
tigens, some of which have been defined using monoclonal an-
tibodies (MoAbs) (5-9).
We have previously shown (9) that an antigen shared by
monocytes and granulocytes, defined by MoAb AML-2-23, can
be induced on cells of the HL-60 line by incubation with either
granulopoietic inducers such as DMSO or by lymphocyte su-
pernatants, but not by phorbol diester treatment. Induction of
differentiation with mixed-lymphocyte culture supernatants
(MLC-SUP) involved primarily the increased expression of cy-
toplasmic a-naphthyl acetate esterase (nonspecific esterase) and
a decreased nuclear/cytoplasmic ratio. In contrast, treatment of
the cells with phorbol diester induced more profound mono-
cytoid differentiation resulting in many of the cells attaching
to plastic surfaces and extending pseudopods. The factors present
in MLC-SUP that induce neoantigen expression as well as his-
tochemical and morphologic changes have previously been un-
known. In this report, we present evidence that immune or
gamma interferon (,y-IFN) is capable of mimicking the activity
of MLC-SUP and we propose that this lymphokine is involved
in the induction of differentiation in the HL-60 line.
Methods
Cells. The HL-60 promyelocytic leukemia cell line (10) was provided
by Dr. Robert Gallo, of the National Institutes of Health, Bethesda,
MD. Cells were continuously cultured in a serum-free defined medium
(modified Iscove's medium [11]). For comparison, a variety of other
1. Abbreviations used in this paper: ADCC, antibody-dependent cellular
cytotoxicity; CE, chicken erythrocyte; CSF-1, colony-stimulating factor-
1; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; IFN, interferon;
MLC-SUP, mixed-lymphocyte culture supernatants; MoAb, monoclonal
antibody.
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culture media were used, including RPMI-1640 (K. C. Biologicals, St.
Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Sterile
Systems Inc., Logan, UT), Immunex modified Iscove's medium (Im-
munex, Inc., Seattle, WA), and Iscove's medium, supplied by K. C.
Biologicals. All media were supplemented with 50 14g/ml of gentamicin
(Schering Corp., Kenilworth, NJ).
Monoclonal antibodies. MoAb AML-2-23, an IgG2b antibody that
reacts strongly with monocytes and less so with granulocytes (8) was
used in this study to monitor phenotypic changes. In addition, the reac-
tivity of MoAbs PM-81(12), PMN 29(8), PMN 6(8), OKIal (Ortho
Diagnostic Systems, Inc., Westwood, MA), 61D3(13), and 63D3(13)
with control and treated cells was determined. Control MoAbs included
AML-1-201 (8), which reacts with ,-2 microglobulin, the IgGI antibody
produced by the P3 hybridoma parent cell line, and an IgG2b MoAb
of irrelevant specificity. All studies were conducted with saturating
amounts of purified MoAbs (20 sg/ml).
To quantify the number ofAML-2-23 binding sites, the Fab portion
of MoAb AML-2-23 was prepared by papain cleavage (14), affinity
chromatography on protein A-Sepharose 4B, and gel filtration on Se-
phadex GI00, and was iodinated by the chloramine T method (15).
Control and treated cells were incubated for 2 h at 4VC with a saturating
dose of '25l-Fab in the presence or absence of excess unlabeled MoAb
AML-2-23. Free and bound antibody were separated by centrifugation
on an oil cushion (16) and the radioactivity in supernatants and cell
pellets was determined. After correcting for nonspecific binding, the
number of AML-2-23 receptor sites per cell was estimated from the
specific activity of the radiolabeled Fab.
Induction ofphenotypic change with IFN. a-, ,-, and 'y-IFN produced
in Escherichia coli from recombinant human DNA (17-19) were gen-
erously provided by Dr. Costa Sevastopoulos (Genentech Inc., San Fran-
cisco, CA) for these studies. The purity of these preparations was >95%
as established by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and silver staining (20). The levels of endotoxin in IFN prep-
arations and media were measured in a Limulus amebocyte assay (21).
Cells from the HL-60 line were seeded at 125,000 cells/ml in six-well
plastic tissue culture plates to which were added varying concentrations
of each of the IFN species. To establish a dose-response relationship,
cells were cultured with increasing concentrations of interferons (0.1-
104 anti-viral U/ml, a-IFN as standard) for 3 d at 37°C in a 5% CO2
humidified atmosphere and removed for morphologic evaluation and
for binding to MoAbs. The morphology of treated and control cells was
evaluated by Wright's-Giemsa stain on cytofuge preparations. Staining
for a-naphthyl acetate esterase was also performed (22). MoAb binding
was evaluated by cytofluorography. A study of the time dependency for
'y-IFN induction was performed during which 500 U of y-IFN was
added serially on each of 7 d to cells previously seeded as above.
Blocking of y-IFN activity by a MoAb to y-IFN. To verify that the
activity being measured in both the y-IFN preparations and MLC su-
pernatants was y-IFN, we attempted to block activity with a MoAb to
y-IFN. An IgGl MoAb that neutralizes 'y-IFN activity was generously
provided for these studies by Drs. Junming Le and Jan T. Vilcek of
New York University Medical Center. 100 U of -y-IFN (in 20 id) or
MLC-SUP (20 u1) was incubated with 20 ul of supernatant (either
diluted 1:10 with medium or undiluted) from the anti-y-IFN hybridoma,
B-3, or the P3 myeloma cell line at 37°C for I h. This mixture was
added to freshly seeded HL-60 cells. To control for the possibility that
immune complexes could nonspecifically block y-IFN activity, we added
a mixture of human nerve growth factor and an IgG MoAb specific for
nerve growth factor to some cultures. In addition, to further ensure
specificity, the B-3 MoAb was added to cultures in the presence of 1%
DMSO. 5 d later, AML-2-23 antigen induction on these and control
cells was determined by cytofluorography. In addition, the ability of
these cells to mediate antibody-dependent cellular cytotoxicity (ADCC)
was measured (see below).
Effect of colony-stimulating factor (CSF-1J) and endotoxin on HL-
60 cells. HL-60 cells were cultured in serum-free medium with increasing
concentrations of purified CSF-1 (1-500 units/ml) (kindly provided by
Dr. Richard Stanley, Albert Einstein Medical College, Bronx, NY) or
endotoxin (0.01-103 ng/ml) (Associates of Cape Cod, Inc., Woods Hole,
MA). After 5 d the cells were analyzed for morphologic change and for
changes in cell-surface antigen expression.
Cytofluorographic analysis. Control and treated cells were incubated
with purified MoAbs at 20 ,g/ml for 30 min at 4VC. After washing with
phosphate-buffered saline (pH 7.4), containing 0.05% sodium azide and
0.1% bovine serum albumin, fluorescein isothiocyanate conjugated-goat
F(ab%)2 antibody directed to mouse antibody (Boehringer Mannheim
Biochemicals, Indianapolis, IN) was added and incubation continued
for 30 min at 4VC. After washing, the cells were analyzed by flow cy-
tometry on the Ortho Cytofluorograph System 50H with the Ortho
computer system 2150 (Ortho Diagnostic Systems, Inc.).
ADCC. ADCC was performed as previously described (23). Briefly,
chicken erythrocytes (CE) freshly drawn into heparin were washed once
and 10 1d of pelleted cells were labeled with 100 gCi [5"Cr]sodium
chromate (New England Nuclear, Boston, MA). Effector HL-60 cells,
cultured as indicated, were mixed in round-bottomed microtiter wells
with an equal volume of labeled CE (1 X 105/ml) and a 10-1 dilution
of a rabbit anti-CE IgG fraction (stock solution 16 mg/ml). After 6 h
incubation at 37°C, half the supernate was removed and assessed for
5'Cr content. Results are expressed as mean±SD of triplicate wells.
Percentage specific cytotoxicity was calculated as follows: 100 X [(release
by effectors + antibody) - (release by effectors without antibody)]/
[maximum lysis - spontaneous release].
Results
Induction ofmorphologic change. Approximately 50% of cells
cultured in the presence of y-IFN exhibited a lower nuclear/
cytoplasmic ratio and the loss of azurophilic granules. The cells
remained in suspension and did not attach to the plastic culture
wells. Sorting of these cells by fluorescence on the cytofluoro-
graph and observation of their morphology on cytofuge prep-
arations revealed that AML-2-23-positive cells were a homo-
geneous population of large cells with abundant agranular cy-
toplasm. Staining oftreated cells for nonspecific esterase revealed
that -60% of cells were induced by Sy-IFN to display strong
cytoplasmic staining while control cells were all negative. a-
and f,-IFN did not induce such morphologic or histochemical
changes. Proliferation ofHL-60 cells was decreased by only 20%
during exposure to a- and fl-IFN for 6 d while y-IFN had no
effect, as determined by [3H]thymidine incorporation. Cells
treated with IFN and control cells were >95% viable as deter-
mined by staining with acridine orange and ethidium bromide.
Measurement ofmonoclonal antibody binding to cells. The
percentage of untreated HL-60 cells bearing the AML-2-23 an-
tigen varied with the medium used. Less than 10% of the cells
cultured in serum-free modified Iscove's medium expressed the
AML-2-23 antigen even when endotoxin at concentrations
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ranging from 0.01 to 103 ng/ml or CSF-1 (1-500 U/ml) was
added (data not shown). The activity of CSF-1 was verified by
its ability to support growth of colonies derived from peripheral
blood mononuclear cells of normal donors in methylcellulose
cultures (24). Cells cultured in RPMI containing 10% FBS, or
in Immunex medium, expressed the AML-2-23 antigen on - 15-
40% of cells probably in response to differentiating agents such
as retinoids which are found in serum.
The experiment shown in Fig. 1 indicates that -50% of
HL-60 cells were induced by y-IFN to express the AML-2-23
antigen. In six experiments, the range of AML-2-23 positive
cells following y-IFN treatment was 50-75%. The effect of y-
IFN was near maximal by day 5 in experiments in which cells
were cultured in medium to which 500 U/ml y-IFN was initially
added (Fig. 2). To control for the possibility that the AML-2-
23 antibody may interact with induced HL-60 cells through Fc-
receptors (25), competing human IgG at 300 ,g/ml was mixed
with AML-2-23 before incubation with treated cells. The degree
ofbinding ofAML-2-23 was unaffected by Fc-receptor blockade.
Radioligand binding data (not shown) using '25I-Fab ofthe AML-
2-23 MoAb indicated that the average number of antigenic
determinants increased from -6,000/cell to 90,000/cell during
culture in the presence of 500 U/ml y-IFN. Cells cultured in
the presence of a- and fi-IFN revealed no change in the level
ofAML-2-23 antigen (<10% positive). The degree of induction
of the AML-2-23 antigen by MLC-SUP was similar to that of
'y-IFN at 500 U/ml.
No significant difference in the binding of MoAbs PM-8 1,
PMN 29, or PMN 6 was noted between control and IFN-treated







in parallel with AML-2-23, as previously reported (9). OKIal
did not bind to HL-60 cells before or after IFN exposure. Of
interest is that the expression of f,-2-microglobulin was found
to be quite low on control cells cultured in serum-free medium
and that y-IFN was capable of inducing this antigen.
Effect ofanti-'y-IFNMoAb on activity ofry-IFNandofMLC-
SUP. As seen in Table II, compared with a control MoAb of
the same IgG subclass, the MoAb to y-IFN, B-3, effectively
neutralized the activity of both purified y-IFN and of MLC-
SUP. No effect of either nonspecific immune complexes on 'y-
IFN-mediated antigen induction (Table II) or the B-3 MoAb
on DMSO-mediated AML-2-23 induction (data not shown) was
noted. Moreover, the MoAb also inhibited the ability of y-IFN
and MLC-SUP to increase ADCC activity (Figs. 3-5).
ADCC. Unstimulated HL-60 cells possessed low levels of
cytotoxicity to antibody-coated CE, with -10% specific cyto-
toxicity at a ratio of 10 HL-60 cells to 1 CE (Fig. 3). Cells
cultured for 5 d under identical conditions in the presence of
y-IFN showed a three to fourfold increase in killing. This dem-
onstrates that recombinant human y-IFN is a potent inducer
of ADCC by HL-60 cells, in line with a previous report that
IgG Fc receptor expression by this cell line is greatly elevated
by recombinant y-IFN (26). Cells cultured with 10 U/ml y-
IFN in the presence of the MoAb specific for y-IFN, B-3, did
not show such strongly elevated cytotoxicity (Fig. 3). Although
these cells still killed more effectively than untreated controls,
the level of cytotoxicity was only half of that achieved by cells
treated with 10 U/ml y-IFN.
Since the degree of cytotoxicity of y-IFN treated cells was
nearly identical over a range of effector to target ratios from 10
Figure 1. Induction of the AML-2-23 an-
tigen on HL-60 cells cultured for 5 d in
serum-free medium in the presence of
each of the three species of IFN. The per-
centage of AML-2-23 positive cells, as de-
.i termined by cytofluorography, increased
from 0 to 45% during exposure to y-IFN
3 0 (e) in a dose-dependent manner, but only
to 8% during exposure to a- (A) or ,B- (o)
IFN. The background staining of control
03 104 MoAb was subtracted from the number
of AML-2-23-positive cells.












to 1.2, other experiments were performed in which lower effector
to target ratios were achieved. As shown in Fig. 4 the degree of
killing was dependent on the ratio of effector to target cells at
low effector to target ratios. Also of interest is the observation
that treatment of HL-60 cells with DMSO did not induce in-
Table I. Effect of y-IFN on Antigen Expression on HL-60
Cells Detected with MoAbs




AML-2-23 2 (10) 51 (40)
PM-81 93 (33) 91 (37)
PMN 29 80 (31) 83 (35)
63D3 0 (0) 57 (20)
61D3 0 (0) 59 (20)
OKIal 0 (0) 0 (0)
AML-1-201 2 (1) 80 (50)
Numbers reported are the percentages of cells stained by MoAb less
the percentages of control MoAb-positive cells (usually 1-2%). The
mean fluorescense intensity (MFI) of MoAb-stained cells was calcu-
lated from the equation: mean = 1/n (n. x), where n is the total
number of cells, n, is the number or cells in channel x, and x is the
channel number. Results are expressed as mean fluorescence of the
experimental sample minus the mean fluorescence of the control.
* Cells were cultured in the presence of 500 U/ml of -y-IFN for 5 d.
5 6
Figure 2. The percentage of AML-2-23
positive cells was dependent on time of
exposure to -y-IFN (500 U/ml). The
mean fluorescence intensity of y-IFN
treated cells increased from 6 on day 0 to
25 on day 7. The background staining of
control MoAb was subtracted from the
number of AML-2-23-positive cells.
Table II. Neutralization by a MoAb to -y-IFN of y-IFN and




1 B-3 12 32
CON 100 100
2 B-3 2 0
CON 100 100
IC 100 ND
* In experiment 1, y-IFN (200 U in 40 sl) or MLC-SUP (40 jsl) were
incubated with an equal volume of supernatant from the hybridoma
producing anti-IFN MoAb, B-3, or control supernatant (CON) (from
the P3 myeloma line) for I h at 370C. This mixture was added in
duplicate to HL-60 cells freshly seeded (3 X 105 cells/ml) into 24-well
cluster plates. In experiment 2, a mixture of an irrelevant immune
complex (IC) (nerve growth factor-anti-nerve growth factor) was
added to some cultures to control for the possibility that immune
complexes accounted for the inhibition of y-IFN by B-3. CON in
this experiment was supernatant from 7SN-60-4, a murine hybri-
doma producing an anti-nerve growth factor IgG MoAb. In both ex-
periments, parallel cultures of HL-60 cells in the presence of y-IFN
(100 U/ml) or MLC-SUP (2% in experiment 1, 10% in experiment 2)
were also conducted. After culture for 5 d, these cells were analyzed
by cytofluorography for the expression of the AML-2-23 antigen. The
fluorescence of cells induced by -y-IFN or MLC-SUP in the presence
of control MoAb was taken as 100%. The relative fluorescence of
cells induced in the presence of specific MoAb to y-IFN, B-3, is
shown.
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Figure 3. Enhancement of an-
tibody-dependent cellular cyto-
-~40 - toxicity by 'y-IFN. The ability
of HL-60 cells cultured for 5 d
30-s;;<T in the presence of y-IFN at 1O
U/ml (A) and 100 U/ml (A)
and control HL-60 cells (-) to
. 20 - kill 5"Cr-labeled CE over aC')
range of effector to target cell
1 + ratios is shown. Neutralization
of y-IFN by a MoAb specific
for y-IFN, B-3, resulted in
10 5 25 1.2 -50% inhibition of the aug-
Effector to Target Ratio mented ADCC activity (o).
creased ADCC activity despite the fact that granulocytic dif-
ferentiation and neoantigen expression (AML-2-23) was induced
on these cells.
Another experiment (Fig. 5) demonstrates blocking ofMLC-
SUP-mediated induction of ADCC by the B-3 MoAb, further
supporting the notion that y-IFN is the active factor in
MLC-SUP.
Discussion
These studies indicate that y-IFN induces phenotypic changes
consistent with monocytoid differentiation in cells of the HL-
60 promyelocytic leukemia cell line. We have previously shown
that MLC-SUP are capable of inducing an identical change in
the phenotype of HL-60 cells and the present report now dem-
onstrates that this effect is duplicated by gene-cloned and es-
sentially pure y-IFN. Neither purified CSF-1 nor endotoxin
were capable of inducing these effects. Since the 'y-IFN con-
centration dependence of this effect is consistent with the levels
of y-IFN normally present in MLC-SUP, it would appear that
the component in MLC-SUP primarily responsible for induction
of monocytoid differentiation is -y-IFN. This interpretation is
supported by the finding that the activity of both the cloned y-
IFN and MLC-SUP was blocked by a specific MoAb to y-IFN.
However, some contribution of other factors cannot be defin-
itively excluded. Moreover, we have shown that the changes
induced by y-IFN are specific to this species of IFN and not
80 Figure 4. The enhancement of HL-60 ADCCby y-IFN but not by DMSO, and the effect
70 of monoclonal antibody to y-IFN. HL-60
60- cells were cultured for 5 d in serum-free Is-
>_ 50 \\^ cove's medium alone (-), or supplemented40- g with 250 U/ml y-IFN (A), -y-IFN plus MoAb
5Z A\ specific for y-IFN (A), y-IFN plus an irrele-
F 30 vant MoAb specific for nerve growth factorC)
-
20 - (o), or 1% DMSO (o). Cells were then com-
- 10 v pared for ability to mediate ADCC against
rabbit IgG-coated chicken erythrocytes in












0 5 1.2 0.3
Figure 5. The enhancement of HL-60 ADCC
by MLC supernatant and the effect of a
MoAb against y-IFN. HL-60 cells were cul-
tured for 5 d in serum-free Iscove's medium
alone (e), or supplemented with MLC super-
natant (10%) (A) or MLC supernatant with
the addition of a MoAb specific for Sy-IFN(A), and then compared for ability to kill
rabbit IgG-coated chicken erythrocytes
in 6 h.
induced by either a- or f3-IFN. The lack of effects with a- and
(-IFNs are consistent with a recent report (27) also showing
that no morphologic, antigenic, or functional changes were in-
duced in the U937 line by these species of IFN.
In addition, these results demonstrate that the antigenic and
morphologic changes induced by y-IFN are accompanied by
an increase in ADCC mediated by these cells. Since the ability
to kill antibody-coated targets is a recognized property of mature
cells of the myeloid series, this increase in cytotoxic capability
appears to be related to overall differentiation of HL-60 cells.
Other data, however, suggest that this interpretation may be an
over-simplification. In particular, cloned 'y-IFN has been shown
to elevate Fc receptors (26) on HL-60 and U937 cells (26) and
ADCC of U937 cells within 18 h (28) although differentiation
of HL-60 as assessed by appearance of the AML-2-23 antigen
did not occur until 48 h. It is possible, therefore, that y-IFN
enhancement of myeloid Fc receptor expression and ADCC
may not be directly linked to differentiation. Further evidence
in support of this notion is the failure of DMSO to induce
ADCC despite the fact that this agent induces granulocytic dif-
ferentiation of HL-60 cells (9).
The results of our study and of others (29, 30) indicate that
IFN has important effects on hematopoiesis. Our findings also
suggest the possibility that human y-IFN may play a regulatory
role in the process ofmonocyte/macrophage commitment from
the myeloid progenitor pool as well as functional activation of
these cells. It is interesting that not all HL-60 cells were inducible
by y-IFN, in contrast to the effects of chemical inducers such
as DMSO or phorbol diester. We are presently studying the
inducibility of individual clones of HL-60, in order to identify
noninducible clones, and, therefore, identify differences between
noninducible and inducible cells.
That y-IFN induces monocytoid changes in the phenotype
of HL-60 cells may have clinical significance. If cells from pa-
tients with acute myelogenous leukemia respond to y-IFN in
a similar manner, this agent could have therapeutic use as a
differentiation agent, possibly in combination with other known
differentiating agents such as the retinoids or 1,25-dihydro;iy-
vitamin D3. In addition to the possibility of terminally differ-
entiating the leukemic clone, the induction of neoantigen
expression could enhance MoAb-mediated cytolysis. Further
studies that address these possibilities with both the HL-60 cell
line and leukemia cells from patients with AML are in progress.
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